An Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus
Latest Information Update: 13 May 2022
At a glance
- Drugs Brexanolone (Primary)
- Indications Status epilepticus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sage Therapeutics
- 05 Aug 2017 Results published in the Annals of Neurology
- 28 Apr 2017 Results assessing the hemodynamic properties of SAGE-547 injection, presented at the 69th Annual Meeting of the American Academy of Neurology.
- 28 Apr 2017 Results of pharmacokinetic assessment of standard and high dosing of SAGE-547 injection, presented at the 69th Annual Meeting of the American Academy of Neurology.